新生儿戒断综合征药物治疗对DNA甲基化与神经行为的影响
该前瞻性队列研究纳入37名新生儿,在吗啡治疗新生儿戒断综合征(NAS)前后采集口腔拭子并评估神经行为。结果显示OPRM1基因4个CpG位点中1个位点的DNA甲基化在治疗后显著下降,神经行为多项指标改善;治疗时长更长、吗啡总剂量更高与DNA甲基化下降幅度更大相关,而DNA甲基化下降越大,兴奋性和肌张力增高改善越明显。
要点
- 吗啡治疗NAS后OPRM1基因4个CpG位点中1个位点DNA甲基化显著下降。
- 治疗后新生儿兴奋性、肌张力增高、嗜睡、应激及戒断征象减少,运动质量和调节能力提高。
- 治疗时长更长和吗啡剂量更高与DNA甲基化下降更大相关,后者与神经行为改善相关。
核心结论
- NAS药物(吗啡)治疗与OPRM1基因DNA甲基化下降及新生儿神经行为改善相关。
- 表观遗传改变可能参与药物治疗后新生儿神经行为的变化。
研究设计与样本
- 前瞻性队列研究,纳入37名接受吗啡治疗的新生儿。
- 在NAS治疗前后采集口腔拭子提取基因组DNA,检测OPRM1基因内4个CpG位点的DNA甲基化。
- 治疗前后采用NICU网络神经行为量表(NNNS)评估,并计算DNA甲基化变化与NNNS总结评分变化。
- 采用路径分析检验药物治疗(治疗时长和吗啡总剂量)、DNA甲基化变化与NNNS总结评分变化之间的关联。
主要发现
- OPRM1基因4个CpG位点中1个位点的DNA甲基化从治疗前到治疗后显著下降。
- 治疗前后比较,新生儿兴奋性、肌张力增高、嗜睡、应激和戒断征象减少,运动质量和调节能力提高。
- 治疗时长更长和吗啡剂量更高与DNA甲基化下降幅度更大相关。
- DNA甲基化下降越大,NNNS上兴奋性和肌张力增高的下降越大。
临床怎么用
- 对于接受吗啡治疗的NAS新生儿,可关注治疗前后神经行为变化,尤其是兴奋性、肌张力、嗜睡、应激与戒断征象及运动质量和调节能力。
- 治疗时长和吗啡总剂量与OPRM1基因DNA甲基化下降幅度相关,提示药物暴露强度可能与表观遗传改变相关。
- DNA甲基化变化与神经行为改善相关,表观遗传指标有望作为理解NAS治疗反应的探索性线索,但尚不能用于临床决策。
局限性
- 样本量仅37名新生儿,结果外推需谨慎。
- 仅检测OPRM1基因4个CpG位点,未覆盖其他候选基因或位点。
- 为观察性前瞻性队列,路径分析不能确立药物治疗、DNA甲基化与神经行为变化之间的因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether pharmacologic treatment for neonatal abstinence syndrome (NAS) is associated with changes in DNA methylation (DNAm) of the mu-opioid receptor gene (OPRM1) and improvements in neonatal neurobehavior. STUDY DESIGN: Buccal swabs were collected from 37 neonates before and after morphine treatment for NAS. Genomic DNA was extracted, and DNAm was examined at 4 cytosine-phosphate-guanine (CpG) sites within the OPRM1 gene. Assessment with the NICU Network Neurobehavioral Scales (NNNS) was also performed before and after NAS treatment. Changes in DNAm (DNAmpost-tx - DNAmpre-tx) and NNNS summary scores (NNNSpost-tx - NNNSpre-tx) were then calculated. Path analysis was used to examine associations among pharmacologic treatment (length of treatment [LOT] and total dose of morphine), changes in DNAm, and changes in NNNS summary scores. RESULTS: DNAm was significantly decreased from pretreatment to post-treatment at 1 of 4 CpG sites within the OPRM1 gene. Neonates also demonstrated decreased excitability, hypertonia, lethargy, signs of stress and abstinence, and increased quality of movement and regulation from pretreatment to post-treatment. Longer LOT and higher morphine dose were associated with greater decreases in DNAm; greater decreases in DNAm were associated with greater decreases in excitability and hypertonia on the NNNS. CONCLUSIONS: Pharmacologic treatment of NAS is associated with decreased DNAm of the OPRM1 gene and improved neonatal neurobehavior. Epigenetic changes may play a role in these changes in neonatal neurobehavior.
引用
- Camerota M, Davis JM, Dansereau LM, et al. Effects of Pharmacologic Treatment for Neonatal Abstinence Syndrome on DNA Methylation and Neurobehavior: A Prospective Cohort Study. J Pediatr. 2021. PMID: 34971656. doi:10.1016/j.jpeds.2021.12.057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。